Skip to main content

Table 3 Multivariate analysis of prognosis in patients with HDCA/CY/TBI compared with CY/TBI

From: Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy

Variables

 

Overall mortality

 

Tumor-related mortality

 

NRM

 

HR

(95 % CI)

p

HR

(95 % CI)

p

HR

(95 % CI)

p

Conditioning

CY/TBI

(Reference)

 

(Reference)

 

(Reference)

 

HDCA/CY/TBI

1.14

(0.96–1.34)

0.13

0.90

(0.72–1.12)

0.34

1.48

(1.15–1.91)

<0.01*

Other variables

 Age

≤49

(Reference)

 

(Reference)

 

(Reference)

 

≥50

1.86

(1.57–2.20)

<0.01*

1.31

(1.02–1.68)

0.03*

2.04

(1.60–2.61)

<0.01*

 PS

0–1

(Reference)

 

(Reference)

 

(Reference)

 

≥2

1.42

(1.09–1.85)

<0.01*

1.73

(1.25–2.39)

<0.01*

0.71

(0.41–1.23)

0.22

 CMV sero-status

Negative

(Reference)

 

(Reference)

 

(Reference)

 

Positive

1.12

(0.93–1.34)

0.23

1.29

(1.00–1.65)

0.05*

0.91

(0.70–1.18)

0.47

 Diagnosis

AML

(Reference)

 

(Reference)

 

(Reference)

 

MDS

0.40

(0.32–0.51)

<0.01*

0.18

(0.12–0.27)

<0.01*

1.18

(0.87–1.59)

0.28

 Disease risk

Standard

(Reference)

 

(Reference)

 

(Reference)

 

High

2.53

(2.18–2.93)

<0.01*

3.98

(3.26–4.85)

<0.01*

0.97

(0.77–1.23)

0.82

 Days from diagnosis to HCT

≤240

(Reference)

 

(Reference)

 

(Reference)

 

≥241

0.88

(0.76–1.01)

0.07

0.80

(0.66–0.97)

0.02*

0.98

(0.79–1.22)

0.89

 HLA mismatch

Matched

(Reference)

 

(Reference)

 

(Reference)

 

Mismatched

1.25

(1.08–1.44)

<0.01*

0.90

(0.73–1.10)

0.30

1.60

(1.29–1.99)

<0.01*

 Sex mismatch

Matched

(Reference)

 

(Reference)

 

(Reference)

 

M to F

0.97

(0.81–1.15)

0.70

0.91

(0.72–1.15)

0.44

1.01

(0.77–1.31)

0.97

F to M

1.12

(0.94–1.33)

0.20

0.94

(0.74–1.20)

0.63

1.28

(0.99–1.65)

0.07

 Year of HCT

≤2008

(Reference)

 

(Reference)

 

(Reference)

 

≥2009

0.89

(0.77–1.02)

0.10

0.96

(0.80–1.16)

0.70

0.76

(0.61–0.94)

0.01*

  1. Other abbreviations are explained in Tables 1 and 2
  2. NRM non-relapse mortality
  3. *Indicates statistically significant
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us